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Abstract
Background: During the peri-implantation period, the embryo adheres to an adequately prepared or receptive
endometrial surface epithelium. Abnormal embryo adhesion to the endometrium results in embryo implantation
failure and infertility. Endometrial epithelial cell plasma membrane proteins critical in regulating adhesion may
potentially be infertility biomarkers or targets for treating infertility. Interleukin (IL) 11 regulates human endometrial
epithelial cells (hEEC) adhesion. Its production is abnormal in women with infertility. The objective of the study was
to identify IL11 regulated plasma membrane proteins in hEEC in vitro using a proteomic approach.
Methods: Using a 2D-differential in-gel electrophoresis (DIGE) electrophoresis combined with LCMS/MS mass
spectrometry approach, we identified 20 unique plasma membrane proteins differentially regulated by IL11 in
ECC-1 cells, a hEEC derived cell line. Two IL11 regulated proteins with known roles in cell adhesion, annexin A2
(ANXA2) and flotillin-1 (FLOT1), were validated by Western blot and immunocytochemistry in hEEC lines (ECC-1 and
an additional cell line, Ishikawa) and primary hEEC. Flotilin-1 was further validated by immunohistochemistry in
human endometrium throughout the menstrual cycle (n = 6-8/cycle).
Results: 2D-DIGE analysis identified 4 spots that were significantly different between control and IL11 treated
group. Of these 4 spots, there were 20 proteins that were identified with LCMS/MS. Two proteins; ANXA2 and
FLOT1 were chosen for further analyses and have found to be significantly up-regulated following IL11 treatment.
Western blot analysis showed a 2-fold and a 2.5-fold increase of ANXA2 in hEEC membrane fraction of ECC-1 and
Ishikawa cells respectively. Similarly, a 1.8-fold and a 2.3/2.4-fold increase was also observed for FLOT1 in hEEC
membrane fraction of ECC-1 and Ishikawa cells respectively. In vitro, IL11 induced stronger ANXA2 expression on
cell surface of primary hEEC and ECC-1 whilst, the lipid-raft protein FLOT1 demonstrated punctate staining in the
apical surface of ECC-1 plasma membranes and was upregulated in the epithelium in the receptive phase of the
menstrual cycle (p lower or equal 0.05).
Conclusions: This is the first study to use a proteomics approach to identify hEEC plasma membrane proteins that
may be useful as infertility markers or pharmacological targets for fertility regulation.
Background
Embryo implantation is a complex process requiring
synchronised endometrial receptivity and blastocyst
competence [1]. The initial apposition, attachment and
adhesion of the blastocyst to an adequately prepared or
receptive maternal endometrium occurs via a co-ordinated
dialogue of locally produced molecules, including cytokines,
adhesion and extracellular matrix (ECM) molecules [2].
Interleukin (IL) 11 belongs to the IL6 family of cyto-
kines and signals via a heterodimeric complex of IL11
receptor (R) a and gp130 [3]. IL11 is absolutely required
for decidualization of endometrial stromal cells and
blastocyst implantation in mice [4-6]. Female mice with
a null mutation of the IL11-Ra are infertile due to a
defective post-implantation response to the implanting
blastocyst. There is evidence supporting the importance
of IL11 in the initial attachment of the human blastocyst
to the endometrium. While IL11 is produced only by
decidual cells post-implantation in mice, in humans
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luminal epithelium in the mid-secretory (receptive)
phase of the menstrual cycle when blastocyst implanta-
tion is most likely to occur [7-10]. Similarly, mid-secre-
tory phase luminal and glandular epithelium express
IL11-Ra [7,8,11,12]. Both epithelial IL11 and IL11-Ra
are dysregulated in the endometrium of infertile women
compared with that of fertile controls [13]. There is a
positive correlation between IL11 levels in uterine flush-
ings (collected during the window of endometrial recep-
tivity) and the responsiveness of women to ovarian
stimulation prior to IVF [14]. This suggests that reduced
IL11 secretion by endometrial epithelial cells during this
time may be responsible for the reduced implantation/
pregnancy rates in excessive ovarian responders during
IVF treatment.
We have previously demonstrated that IL11 regulates
epithelial cell adhesive properties suggesting that IL11
regulates cell surface proteins to facilitate the adhesion
of the blastocyst to the endometrial epithelium [15].
T h ed o w n s t r e a mm e c h a n i s m sb yw h i c hI L 1 1r e g u l a t e s
endometrial epithelial cell adhesion are poorly
understood.
The aims of the present study were to compare the
protein profiles of IL11 treated and untreated human
endometrial epithelial cell membranes by 2D-DIGE and
identify the differentially expressed proteins by mass
spectrometry (MS). The second aim was to validate
some of the differentially regulated proteins by Western
immunoblotting and to determine their cellular location
in human endometrium by immunohistochemistry. This
is the first study to use a proteomic approach to define
t h em e c h a n i s m sb yw h i c hI L 1 1r e g u l a t e se n d o m e t r i a l
plasma membrane proteins. This study has identified
two proteins, which are known regulators of cell adhe-
sion and are likely to be critical for endometrial epithe-
lial cell adhesion, a process that is absolutely required
for embryo implantation.
Methods
Patients and tissues
Endometrial tissues were obtained at curettage from
women with normal menstrual cycle (ranging from d28-
32) and no apparent endometrial dysfunction that were
scheduled for tubal ligation or were undergoing testing
for tubal patency. The stage of the cycle was determined
from the patient’s testimony and confirmed histologi-
cally by a qualified gynecological pathologist. The age
range of the women was 32-40 years. For immunohisto-
chemistry studies: endometrial samples were collected
across different stages of the menstrual cycle (n = 6-8/
cycle); menstrual (d1-4), proliferative (d5-14), early
secretory (d15-19), mid-secretory (d20-24) and late
secretory (d25-32) phases. Written informed consent
was obtained from each patient and the study was
approved by Southern Health Human Research and
Ethics committee. All endometrial biopsies were fixed
overnight in 4% neutral buffered formalin, prior to rou-
tine paraffin embedding.
Cell culture
Human endometrial tissues were digested with collage-
nase (n = 6), and the suspension was filtered through 43
and 11 μm nylon mesh to collect endometrial epithelial
glands, as previously described work [15]. The cells/
epithelial fragments were collected and re-suspended in
a 1:1 mixture of DMEM/Hams F-12 (F12; Thermo Elec-
tron Corp., Melbourne, Australia) supplemented with
10% fetal calf serum (FCS; Invitrogen, Carlsbad, CA), 2
mM L-glutamine (Thermo Electron), and 1% antibiotic-
antimycotic solution (Life Technologies, Inc., Auckland,
New Zealand) and plated. Endometrial epithelial cells
(hEEC) were collected from the filter paper and further
purified through selective adherence. Briefly, epithelial
glands were serially repeated (three times) in plastic cul-
ture dishes for 30 min to allow adherence of contami-
nating stromal cells. Non-adherent cells/glands were
transferred to 24-well plates and epithelial cells were
allowed to grow out from glandular structures for 48 h.
A purity of greater than 95% was necessary for the cells
to be used experimentally. Confluent hEEC were cul-
tured in serum-free 1:1 DMEM/F12, 2 mM L-glutamine,
and 1% antibiotic-antimycotic solution. Confluent cells
of 4-6 wells of 24 well plates of pure primary hEEC
were used as starting material (approximately 0.2 million
cells).
The endometrial epithelial carcinoma cell line; ECC-1
and Ishikawa cells were cultured in DMEM/F12 (1:1)
and DMEM respectively (Invitrogen, Victoria, Australia)
supplemented with 10% fetal calf serum (SAFC Bios-
ciences, Victoria, Australia), 1% L-glutamine (Sigma-
Aldrich Pty. Ltd, Sydney, Australia) and 1% antibiotic-
antimycotic (Invitrogen, Victoria, Australia). Confluent
cells (1 × T175 cm
2 flask, starting material of approxi-
mately 15 million cells) were transferred into their
r e s p e c t i v es e r u mr e d u c e d( 1 %F C S )m e d i u mf o r2 4h
prior to treatment. For proteomic analyses, only ECC-1
cells were used but an additional cell line; Ishikawa cells
was also included in the proteomic validation. There
were two different treatment groups (n = 4 per group)
of control (media alone) and IL11 (100 ng/ml, concen-
tration of IL11 determined from previous studies in
endometrial cells) [15]. An additional group of IL11
(500 ng/ml) was included for validation of proteomic
analyses by Western blot. For Western blot validation,
1×T 7 5c m
2 flask of confluent cells per treatment was
used as starting material (approximately 5-6 million
cells) (n = 3 in duplicate per treatment group).
Yap et al. Reproductive Biology and Endocrinology 2011, 9:73
http://www.rbej.com/content/9/1/73
Page 2 of 15Protein extraction and membrane purification
Prior to protein extraction, cells were washed ten times
with phosphate buffered saline free of Ca
2+ and Mg
2+
(PBS
-) and collected in Tris buffer (pH 7.4) containing
protease inhibitor cocktail set (Calbiochem, Darmstadt,
Germany). All subsequent steps were performed on ice.
Cellular membrane protein extraction
Briefly, the cell lysates were homogenised by repeated
passaging through a syringe and needle, using both 21
G and 25 G needles. This was followed by centrifugation
at 800 g for 15 min at 4°C, after which the supernatant
was transferred to a fresh tube and the pellet re-
extracted as above. The two supernatants were com-
bined and centrifuged using the Optima™ TXN ultra-
centrifuge (Beckman Coulter, Inc., USA) at 100,00 g for
45 min at 4°C. The supernatant containing soluble cyto-
solic proteins was transferred to a fresh tube and snap
frozen at -80°C. An aliquot (cytosol (C)-fraction) was
collected for later analysis by Western blot for purity.
The pellet was re-suspended with Tris buffer and centri-
fugation repeated as above. The supernatant was dis-
carded and the protein pellet containing crude
membrane proteins was re-suspended in solubilisation
buffer (40 mM Tris, 7 M urea, 2 M thiourea, 1% (w/v)
C7BzO (3-(4-Heptyl)phenyl-2-hydroxypropyl) dimethy-
lammoniopropanesulfonte). An aliquot (membrane (M)-
fraction) was collected for analysis by Western blot for
purity.
Total cellular protein extraction
Briefly, the cell lysates were lysed and scraped in the
buffer mentioned above. Cell extracts were then centri-
fuged at 280 g for 30 min at 4°C and supernatant col-
lected for analysis by Western blot.
Protein concentration measurement
The protein concentrations of membrane samples were
determined using Bradford Assay kit (Bio-Rad, Hercules,
CA) according to manufacturer’s instructions. Subse-
quently, membrane proteins were precipitated with acet-
one for 90 min, centrifuged at 10,000 g for 20 min at
room temperature. The protein pellet was air dried and
then dissolved in labeling buffer (30 mM Tris/HCL, pH
8.1, 7 M urea, 2 M thiourea, 1% (w/v) C7BzO). The final
protein concentration was adjusted to 5 μg/μlw i t h
labeling buffer, snap frozen on dry ice and stored at -80°
C until use.
Western blot analysis
To investigate the purity of membrane isolation, Wes-
tern blot analyses were performed. Both Membrane (M)
and Cytosol (C) fraction extracts were resolved on 11%
SDS-PAGE gels and transferred to nitrocellulose mem-
branes. The same amount of protein (30 μg) was loaded.
All membranes were incubated with Ponceau-S (Sigma)
to ensure equal protein loading in all lanes. The mem-
branes were blocked with 5% nonfat dry milk in TBS
with 0.1% Tween 20 (Bio-Rad Laboratories, Hercules,
CA). Each membrane was then incubated with one of
the following primary antibodies (at a dilution of 1:500
in 5% skim milk/TBS) at 4°C overnight. Primary antibo-
dies included mouse monoclonal anti-Na/K-ATPase,
rabbit polyclonal anti-GRP94 (glucose-regulated protein
94 kDa), mouse monoclonal anti-Ku-86 and mouse
monoclonal anti-GAPDH (all were from Santa Cruz
Biotechnology Inc.; Santa Cruz, CA) for detecting
plasma membrane, endoplasmic reticulum, nuclear and
cytoplasm markers, respectively. After washing with
0.2% Tween-20/TBS, the membranes were further incu-
bated with respective secondary antibodies conjugated
with horseradish peroxidase (1:2000 in 5% skim milk/
TBS) (Dako Cytomation Glostrup, Denmark) at room
temperature for 1 h. HRP activity was detected using
enhanced chemiluminescence reagent (Pierce, Rockford,
IL, USA).
2D-DIGE labeling of membrane proteins
Fluorescent labeling of proteins was performed using
minimal CyDye labeling methodology as described by
the manufacturer (GE Healthcare Bioscience, Uppsala,
Sweden) and detailed elsewhere [16,17]. Briefly, labeling
was carried out on ice in the dark using 200 pmol dye
per 50 μg protein at a protein concentration of 5 μg/μl
for 30 min. The labeling reaction was quenched by the
addition of 1/10 vol of 10 mM lysine. Samples were
either labeled with Cy3 or Cy5 with an internal standard
(comprised of equal amounts of protein from each sam-
ple) labeled with Cy2. On completion of labeling, the
samples were combined as recommended by the manu-
facturer. The combined samples were then precipitated
in acetone as described above and the dried protein pel-
let re-suspended in 450 μl of the solubilisation buffer
(40 mM Tris, 7 M urea, 2 M thiourea, 1% (w.v) C7BzO)
prior to isoelectric focusing.
Isoelectric focusing (IEF) was performed using 24 cm
immobilized pH gradient strips (IPGs) covering the pH
range of 3-10, Tracking Dye, DTT to 100 mM and
ampholytes to 0.5% (v/v) were added and each sample
loaded by passive rehydration for 6 h at RT [17]. IPG
strips were focused overnight using an IPGphor instru-
ment (GE Healthcare, BUCKS, UK), according to the
following profile: current limited to 60 μA per strip, 100
V for 90 min, 300 V for 90 min, 500 V for 3 h, gradient
to 1000 V for 4 h, gradient to 8000 V for 3 h and then
constant 8000 V overnight until reaching between 60
000 and 80 000 Vh. Following focusing, the strips were
incubated in 10 ml of equilibration buffer (50 mM Tris/
HCL, pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v)
SDS, 0.01% (w/v) bromophenol blue) for 20 min on a
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was performed on 8-16% gradient polyacrylamide gels
(24 × 24 cm) overnight in a BioRad Dodeca cell (Rich-
mond, CA) at 50 V as described by the manufacturer.
The run was terminated when the dye front had reached
the bottom of the gel.
2D gels were scanned using a Fuji FLA5100 laser
scanner (Fujifilm, Tokyo, Japan) at excitation wave-
lengths of 473, 535 and 635 nm and with specialty dual
wavelength emission filters for Cy2, Cy3 and Cy5
respectively. Image alignment, spot detection, back-
ground removal and expression analysis were performed
using PG240 SameSpots software (Nonlinear Dynamics,
Newcastle Upon Tyne, UK).
Protein identification by LCMS/MS mass spectrometry
Spots of interest were excised from the gel using a Pro-
PicII robotic spot picker (Genomic Solutions, MI) based
on X-Y coordinates exported directly from PG240
SameSpots. Protein identification by MS/MS was carried
out as described [17]. Monoisotopic peak masses were
automatically extracted using GPS Explorer software
(v3.0 build 311; Applied Biosystems, CA) and peak lists
searched against non-redundant UniProtKB/Swiss-Prot
database (release 56.2; 20407 human sequence entries)
[18] using the MASCOT search engine (updated 03/01/
2007) [19]. Species was restricted to Homo sapiens, car-
bonylamide-cysteine (CAM, fixed modification) and oxi-
dation of methionine (variable modification) were taken
into account, a parent ion mass tolerance of 60 ppm
and 1 missed cleavage (trypsin) was allowed. Up to fif-
teen of the most intense peptides detected in each MS
scan were automatically selected for MS/MS analysis.
Peak lists were extracted using Data Analysis software
version 3.4 (Bruker Diagnostics, Germany). The para-
meters used to create the peak list (version 1.1, Matrix
Science) were a mass range of 700-5000 Da and signal-
to-noise threshold of 5, against the UniProtKB/Swiss-
Prot database as above, with fragment mass tolerance of
0.1 Da. Protein identities were assigned using the follow-
ing criteria to evaluate the search; MOWSE score, num-
ber and intensity of peptides matched, and direct
correlation between the identified protein, its estimated
molecular mass and pI determined from the 2D gel (see
Additional file 1, Table S1).
Validation of proteins by Western blotting
Total lysates and membrane proteins extracted from
control and IL11 treated cells for both endometrial
epithelial cell lines (ECC-1 and Ishikawa) were resolved
on 11% SDS-PAGE gels and transferred to nitrocellulose
membranes. 0.1 μga n d1 0μg of membrane protein
were used for validation of ANXA2 and FLOT1 respec-
tively. However, higher membrane protein load was
needed for validation in the primary EEC. Furthermore,
all membranes were incubated with Ponceau-S (Sigma)
to ensure equal protein loading in all lanes. Non-specific
bindings were blocked with 5% nonfat dry milk in TBS
with 0.1% Tween 20 (Bio-Rad Laboratories, Hercules,
CA) and probed separately with antibodies specific for
ANXA2 (Abcam, UK, # 41803) and FLOT1 (Cell Signal-
ling Inc., US, #3253) at 4°C overnight. The membranes
were washed in TBS with 0.2% Tween 20 and incubated
for 1 h with horseradish peroxidase (HRP)-conjugated
rabbit secondary antibody (1:2000; Dako Cytomation
Glostrup, Denmark). HRP activity was detected using
enhanced chemiluminescence reagent (Pierce, Rockford,
IL, USA). All in vitro cell culture experiments were car-
ried out in 3 independent experiments.
Validation of proteins by immunohistochemistry
Formalin-fixed human endometrial biopsies
Localisation of FLOT1 across the menstrual cycle was
examined in endometrial tissue sections from different
phases of the cycle (menstrual, n = 7; proliferative, n =
8; early secretory, n = 8; mid-secretory, n = 7, late
secretory, n = 9) using the same antibody as employed
for Western blotting. In brief, paraffin sections (5 μm)
were dewaxed in histosol, dehydrated in a graded ser-
ies of ethanol and then microwaved at high power
(700 W) in 0.01 M citric acid buffer (pH 6.0) for
5 min. Endogenous peroxidase activity was quenched
with 6%H2O2 in 100% methanol (1:1 v/v) for 10 min
in the dark at room temperature. Non-specific binding
was blocked by incubation with non-immune blocking
solution of 10% normal goat serum and 2% normal
human serum, diluted in 1 × Tris-buffered saline
(TBS) for 30 min. Primary antibody was diluted 1:100
(Cell Signalling Inc., US, #3253) in blocking solution
and applied overnight at 4°C. Antibody localisation was
detected by sequential application of biotinylated goat
anti-rabbit IgG diluted 1:200 in blocking solution for
30 min and an avidin-biotin complex conjugated to
HRP (Vectastain ABC Elite kite; Vector Laboratories,
Burlingame, CA, USA). The substrate used was diami-
nobenzidine (DAB) (Zymed, San Francisco, USA)
forming an insoluble brown precipitate. Sections were
counterstained with Harris hematoxylin (Sigma Chemi-
cals, St. Louis, MO), dehydrated and mounted with
DPX. Negative isotype controls were included for each
section where non-immunised rabbit IgG was substi-
tuted at matching concentration to the primary anti-
body. Positive control of human tonsil was also
included in the run.
The relative intensity of the immunostaining was
scored semi-quantitatively by two independent observers
on a scale of 0 (no staining) to 3 (maximal staining) in
each of the cellular compartments.
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ECC-1 immunocytochemistry
Both primary hEEC and ECC-1 cells were cultured in
control (media only) and IL11 (100 ng/ml) for 24 hr.
Cells were trypsanised and cell suspension collected and
centrifuged at 438 g for 10 min. The supernatant was
discarded and cell pellet re-suspended in 1 ml of PBS
-.
200 μl (containing 300,000 cells/ml) was applied per
well (4 well chamber) by cytocentrifugation at 4000 U/
min (Hettich Centrifuge, Universal 16A) for 10 min.
Slides were air-dried overnight at room temperature,
then fixed in 70% ethanol for 10 min.
Immunocytochemistry was carried out as above.
Briefly, primary antibody was diluted 1:2000 and 1:1000
(ANXA, Abcam, UK, # 41803) and 1:20 and 1:50
(FLOT1, Cell Signalling Inc., US, #3253) respectively for
primary hEEC and ECC-1 cells in blocking solution and
applied overnight at 4°C. Cytospins were used instead of
chamber slides for immunohistochemistry to validate as
we have previously trialled seeding the monolayer cells
onto glass chamber slides that are suitable for immuno-
histochemistry but the cells did not adhere well.
Statistical analysis
Fold changes and all statistical analyses for proteomic
analyses were calculated based on normalised spot
volumes where the internal standard was used to per-
form normalisation using PG240 SameSpots software.
Statistical analysis of immunoblotting and immunohisto-
chemistry results was carried out using GraphPad Prism
(GraphPad Software Inc., CA), with all data expressed as
mean ± SEM. Statistical analysis of endometrial immu-
nostaining intensity was performed using one-way
ANOVA with Bonferroni’s post-test, while for Western
blot analysis student’s t-test was used. A p value ≤ 0.05
was considered statistically significant.
Results
The membrane and cytosol fractions were isolated from
the human endometrial epithelial cell (hEEC) line, ECC-
1, using several centrifugation steps. To test for cell
membrane protein purity, we compared the two frac-
tions obtained in our isolation method (Membrane [M]
and Cytosol [C]) using different organelle markers. An
equal amount of protein for the M and C fractions was
subjected to Western blot analysis (Figure 1) to examine
the abundance of (A) Na/K-ATPase, (B) GRP94, (C) Ku-
86 and (D) GAPDH which are plasma membrane, endo-
plasmic reticulum, nuclear and cytoplasm markers
respectively. Na/K-ATPase protein was observed only in
the M fraction, indicating a successful enrichment of
plasma membrane proteins in the M fraction. In con-
trast to Na/K-ATPase, GRP94 and Ku-86 were present
in both fractions (M and C fractions) but GRP94 protein
abundance was slightly higher in the C fraction com-
pared to the M fraction, while the abundance of Ku-86
was equal between the M and C fractions. GAPDH pro-
tein was maximal in the C fraction. Ponceau-S was used
to examine the level of protein for each sample trans-
ferred to the nitrocellulose membrane during Western
blot analysis (data not shown) in addition to loading of
equal amounts of proteins.
Characterisation of proteomic profiles on the membrane
surface of ECC-1
The abundance of membrane proteins in ECC-1 cells
treated with IL11 or diluent control was assessed by
2D DIGE (analytical replicates of 4 independent
experiments). A total of 866 spots were resolved by the
2D DIGE analysis following treatment with IL11 (Fig-
ure 2A). Protein spots displaying statistically significant
changes between the control and IL11 treatment
groups (p ≤ 0.05) were considered to be present at
altered levels. Thirteen spots were significantly altered
between the IL11 treated and diluent control-treated
ECC-1 cell membranes (Figure 2A). Four protein spots
(Figure 2B) that were altered between IL11 and con-
trol-treated cells were chosen for identification by
mass spectrometry based on the following criteria: a
fold change of ≥ 1.3 and a spot volume of ≥ 8000,
both cross-referenced with the ability to visualise the
spot on the gel. Twenty unique proteins were identi-
fied by MS analysis and are summarised in Table 1.
Each spot analysed by mass spectrometry contained a
mixture of proteins.


 	


 
 

 




Figure 1 Evaluation of the purity of the cell membrane
isolation method. Cells were subjected to crude isolation of
Membrane (M) and Cytosol (C) fractions. Western blot analysis of
the different markers - (A) Na/K-ATPase (plasma membrane), (B)
GRP94 (endoplasmic reticulum), (C) Ku86 (nuclear) and (D) GAPDH
(cytosol). (M) Membrane, (C) Cytosol and (Mw) molecular weight
marker (kDa).
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Figure 2 Representative 2D SDS-PAGE image of proteins from the human endometrial carcinoma epithelial cell line (ECC-1). Proteins
(150 μg) extracted from membrane fraction of ECC-1 cells were separated by 2D PAGE (first dimension pH 3-10, second dimension 8-16%
polyacrylamide gradient). (A) A representative gel of the pooled internal standard (Cy2) is shown. Overall 866 spots were resolved. Proteins were
clustered according to similarities in their expression patterns (grouped by colours). (B) Differentially expressed proteins were identified and spots
of interest were chosen for further analysis by LCMS/MS are numbered and indicated by circles.
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between IL11 treated and control treated hEEC cells
Protein changes observed between IL11 and control
treated cells were validated by Western blotting and
immunocytochemistry. Proteins were validated by wes-
tern blot in two hEEC cell lines: ECC-1 and Ishikawa
cells whilst, immunocytochemistry was carried out in
ECC-1 cells and primary hEEC. Endometrial biopsies
were also used to assess the cellular localisation and
relative level of protein production in vivo. Immunohis-
tochemical validation was performed using endometrial
tissues from women with normal fertility throughout
the menstrual cycle (n = 6-8/cycle).
IL11 increased Annexin A2 and Flotillin-1 proteins in hEEC
membranes
DIGE analysis identified that annexin A2 (ANXA2) in
protein spot 9 (Table 1) was significantly increased fol-
lowing IL11 treatment. A mixture of four proteins were
identified in spot 9 and ANXA2 was chosen due to the
highest number of peptides present in the analyses and
our interest in its biological function. Western blot ana-
lysis revealed that ANXA2 was present as a single band
Table 1 Assigned Protein Identification Using LC-MS/MS
Spot p-
value
Fold-
change
Protein ID ACC. No.
(Swissprot)
Gene Sequence
coverage (%)
No. peptides
identified
Mr/
pI
9* 0.02 1.33 Annexin A2 P07355 ANXA2 38.6 13 38/
7.56
Ribose-phosphate pyrophosphokinase 1 P60891 PRPS1 15.1 4 35/
6.56
Voltage-dependent anion-selective channel
protein 2
P45880 VDAC2 17.70 5 32/
7.5
Dual specificity mitogen-activated protein
kinase kinase 6
P52564 MAP2K6 11.4 3 37/
7.01
14* 0.04 1.40 Flotillin-1 O75955 FLOT1 62.3 23 47/
7.08
Alpha-enolase P06733 ENO1 6.68 2 47/
6.99
16* 0.04 -1.32 Cdc42-interacting protein 4 Q15462 TRIP10 50.6 22 69/
5.55
78 kDa glucose-regulated protein (GRP78) P11021 HSPA5 47.6 32 72/
5.01
Collagen type IV alpha-3 binding protein Q9Y5P4 COL4A3BP 20.7 9 71/
5.29
NADH-ubiquinone oxireductase 75 kDa
subunit, mitochondrial
P28331 NDUFS1 13.2 8 79/
5.42
Stress-70 protein, mitochondrial P38646 HSPA9 11.5 7 74/
5.44
22* 0.04 -1.32 cDNA FLJ5299 A8K781 cDNA
FLJ5299
47.0 17 47/
5.11
Keratin, type II cytoskeletal 8 P05787 KRT8 46.8 25 48/
5.34
Thioredoxin domain-containing protein 5 Q8NBS9 TXNDC5 27.3 11 48/
5.37
Actin, cytoplasmc 1 P60709 ACTB 26.4 9 42/
5.29
26S protease regulatory subunit 6B P43686 PSMC4 22.7 9 47/
5.09
Uncharacterised protein KIAA0174 (ISTI
homolog)
P53990 KIAA0174 14.6 5 40/
5.22
Eukaryotic initiation factor 4A-1 P60842 EIF4A1 16.0 5 46/
5.32
Hsc70-interacting protein P50502 ST13 12.5 4 41/
5.18
Heterogenous nuclear ribonucleoprotein F P52597 HNRNPF 19.3 4 46/
5.38
a Asterisk (*) denotes spots identified as containing a mixture of 2 or more proteins, or where protein isoforms cannot be distinguished based on peptides
identified.
P-value and fold-change obtained based on normalised spot volume between control and IL11 treated group.
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significantly increased in the membrane protein fraction
in IL11 treated compared to control in both the primary
hEEC (Figure 3A, right panel) and hEEC-derived cell
lines; ECC-1 (Figure 3B, left panel) and Ishikawa (Figure
3C, left panel) but no differences were observed in the
total protein fractions of IL11 treated compared to con-
trol treated primary hEEC (Figure 3A; left panel). How-
ever, there appear to be a difference in abundance in
IL11 treated membrane fraction but no difference in the
cytosol fraction in both the control or IL11 treated (Fig-
ure 3A; right panel). In addition, Western blot showed
that ANXA2 abundance was upregulated 2-fold and 2.5-
fold in IL11 treated compared to control in the cell
membrane fraction in both ECC-1 (100 ng/ml, p ≤ 0.05)
(Figure 3B; right panel) and Ishikawa cells (100 ng/ml, p
≤ 0.05) (Figure 3C; right panel) respectively. Na
+/K
+-ATPase was used as an internal loading control in
addition to Ponceau-S staining to visualise equal loading
(data not shown). Equal concentrations of total mem-
brane protein was loaded per fraction as detailed in the
methods section.
Flotillin-1 (FLOT1) (spot 14; Table 1) was also identi-
fied to be significantly increased following IL11 treat-
ment. Western blot revealed that FLOT1 was present as
a single band of molecular weight ~49 kDa (Figure 4A-
C). There was no difference in FLOT1 total protein in
the IL11 treated compared to control treated primary
hEEC (Figure 4A). However, quantitative analysis
demonstrated a 1.8-fold (100 ng/ml; p ≤ 0.05) and 2.3/
2.4-fold (100 and 500 ng/ml; p ≤ 0.05) increase in total
FLOT1 protein abundance on the cell surface mem-
branes of ECC-1 (Figure 4B; right panel) and Ishikawa
cells respectively (Figure 4C; right panel). 78 kDa glu-
cose-regulated protein (GRP78) was also analysed by
Western blot of primary hEEC membranes, however,
following IL11 treatment there was no statistically sig-
nificant decrease in abundance compared to control
treated cells (data not shown).
Immunolocalisation of ANXA2 and FLOT1 in hEEC cells and
human endometrial tissue
Immunolocalisation for ANXA2 in human endometrial
epithelium during the secreto r yp h a s eo ft h em e n s t r u a l
cycle has previously been demonstrated [20]. IL11 treat-
ment induced stronger ANXA2 expression on the cell
surface of primary hEEC (Figure 5B-C) and ECC-1 (Fig-
ure 5E-F) cells in vitro. Negative isotype IgG control tis-
sues did not stain positively (Figure 5A, D).
Localisation of FLOT1 in human endometrium
throughout the menstrual cycle revealed that FLOT1
was restricted to the glandular epithelial cells (Figure
6A-D and 6G). Maximal staining for FLOT1 was
observed in the mid-secretory phase endometrium and
was significantly more intense (p ≤ 0.0001) in the glands
of the mid-secretory phase endometrium compared to
all other phases (Figure 6J). In the endometrial epithelial
cells, strong punctate staining for FLOT1 was present in
the apical surface of the plasma membranes, while less
intense staining was present basolaterally (Figure 6D).
Intense punctuate staining was also observed in the api-
cal cell surface in luminal epithelial cells only in the
mid-secretory phase of the cycle (Figure 6E). Luminal
epithelial cells from all other phases of the menstrual
cycle did not show positive staining for FLOT1 (data
not shown). Mild staining for FLOT1 was observed in
the vascular endothelial and smooth muscle cells in mid
and late secretory phase endometrium (Figure 6F and
6H). Semi-quantitative analysis revealed that there is a
significant increase of FLOT1 expression in the mid-
secretory phase of the endometrium (Figure 6J). A positive
control of human tonsil was also included and demon-
strated positive staining (Figure 6I). Negative isotype IgG
control tissues shown as insets in Figure 6A-D,G.
We further examined FLOT1 localisation in both pri-
mary hEEC and ECC-1 cultured cells. FLOT1 localised
to both the membrane and cytosolic (Figure 7A-D)
component of the cells but it was enhanced following
IL11 treatment, with stronger punctate staining in pri-
mary hEEC isolated from the proliferative stage of the
menstrual cycle (Figure 7B) and membrane staining in
ECC-1 cells (Figure 7F). There was no effect in hEEC
isolated during the secretory stage (data not shown).
Discussion
Several studies have previously sought to define the
importance of IL11 in facilitating embryo implantation
in mice and in humans [4,9,15]. In vitro, IL11 regulates
hEEC adhesive properties however, to date no proteins
have been identified to act downstream of IL11 on the
membrane surface that may facilitate cell adhesion. In
this study, we identified two candidate proteins
(ANXA2 and FLOT1) upregulated by IL11 in the endo-
metrial epithelial cell membrane using a 2D-DIGE
approach. Here, we found that IL11 up-regulated mem-
brane ANXA2 in both endometrial epithelial cell lines
and also primary hEEC. Interestingly, assessment of
total protein in primary hEEC showed no differences in
ANXA2 expression, suggesting that IL11 did not
regulate total ANXA2, highlighting the importance of
pre-fractionating cellular proteins prior to proteomic
analysis.
This study also identified that IL11 treatment of ECC1
cells down-regulated a number of spots with a maximal
fold decrease of 1.32. We validated one identified down-
regulated protein, GRP78, in ECC1 and primary hEEC
by Western blot. While we did show a slight decrease in
GRP78 protein abundance following IL11 treatment
compared to control, this did not reach statistical
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Figure 3 Western blot analysis of IL11 regulated Annexin A2 (ANXA2) protein in human endometrial epithelial cell (hEEC) membranes
and in total cellular protein. The hEEC cell lines, ECC-1 and Ishikawa and primary hEEC cells were treated without (diluent control) or with
IL11 (100 and/or 500 ng/ml) for 24 h and membrane proteins extracted as described in the Methods. Cell lysates were electrophoresed by
SDS-PAGE and immunoblotted with ANXA2 in (A) total primary hEEC protein lysates (30 μg; left panel) and membrane primary hEEC (1 μg; right
panel), (B) ECC-1 (0.1 μg) and (C) Ishikawa (0.1 μg) cells. Na
+/K
+-ATPase is used as a loading control for membrane proteins. Data is shown as a
single photomicrograph representative of 3 independent experiments. * P ≤ 0.05; t-test.
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Figure 4 Effect of IL11 on flotillin-1 (FLOT1) in human endometrial epithelial cell (hEEC) membranes and in total cellular protein.T h e
hEEC cell lines, ECC-1 and Ishikawa and primary hEEC cells were treated without (diluent control) or with IL11 (100 and/or 500 ng/ml) for 24 h
and membrane proteins extracted as described in the Methods. Cell lysates were electrophoresed by SDS-PAGE and immunoblotted with FLOT1
in (A) total primary hEEC protein lysates (30 μg), (B) ECC-1 (10 μg) and (C) Ishikawa (10 μg) cells. Na
+/K
+-ATPase is used as a loading control for
membrane proteins. Data is shown as a single photomicrograph representative of 3 independent experiments. * P ≤ 0.05; t-test.
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senting the overall fold change of the spot rather than
of the individual proteins. We did however, validate the
upregulated protein ANXA2: Annexin A2 is a calcium-
dependent phospholipid binding protein [21] and is pre-
sent in intracellular, membrane and secreted forms
[21,22]. ANXA2 interacts with cell matrix and proteases
to regulate cell migration and adhesion - for instance it
can act as a receptor for secreted serine proteases on
endothelial cells [23,24]. In a study investigating the
endometrium of women using IUDs for contraceptive
purposes, ANXA2 was shown to be up-regulated in the
receptive compared to the pre-receptive endometrium
[20]. Numerous studies show ANXA2 is involved in cell
adhesion and actin cytoskeletal rearrangements
[23,25,26] as well as increasing cell adhesion molecule
production [27]. Therefore, we suggest that ANXA2
expression on the epithelial membrane surface predis-
poses the epithelium to being receptive towards blasto-
cyst attachment during embryo implantation.
FLOT1 immunolocalisation to the endometrial gland-
ular and luminal epithelium was maximal during the
receptive phase of the menstrual cycle, correlating with
the period of maximal IL11 immunolocalisation [7-10].
Up-regulation of membrane bound FLOT1 upon IL11
stimulus was also found here in both cell lines. Conver-
sely, localisation of FLOT1 in cultured primary hEEC
was maximal upon IL11 stimulus in hEEC isolated dur-
ing the proliferative stage but there was no difference in
hEEC isolated during the secretory stage. We suggest
Immunostaining- Annexin A2 (ANXA2)
A
Primary hEEC cells
B C
DEF
ECC-1 cells
Figure 5 Photomicrograph representing immunocytochemical staining for annexin A2 (ANXA2) in human endometrial epithelial cells
(hEEC). Primary hEEC and the cell lines ECC-1 were treated with diluent or IL11 (100 ng/ml) for 24 h. Cytospins were prepared and subjected to
immunocytochemistry as described in the Materials & Methods. Positive staining for ANXA2 showed as brown pigment with blue nuclear
counterstain. (A, D) Negative IgG (B) Control primary EEC (C) IL11 100 ng/ml primary hEEC (E) Control ECC-1 (F) IL11 100 ng/ml ECC-1. Bars
represent 200 μm.
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Figure 6 Photomicrograph representing immunohistochemical staining for flotillin-1 (FLOT1) in human endometrial tissue throughout
the menstrual cycle and in ECC-1 cells. Positive staining for FLOT1 showed as brown pigment with blue nuclear counterstain. (A) Menstrual,
d1-4 (B) Proliferative, d5-14 (C) Early-secretory, d15-20 (D-F) Mid-secretory, d21-24 (G-H) Late-secretory, d25-d27. (GE) Glandular epithelial, (LE)
Luminal epithelial. Insets in each case are matched negative controls. Positive control of human tonsil included (I). Bars represent 200 μm. Semi-
quantitative analysis of staining intensity for FLOT1 in GE (J). Data represented as mean ± SEM. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, Kruskal
Wallis test, with Dunn’s post-hoc test.
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epithelium during the secretory stage, thus, it was not
possible to detect an increase in FLOT1 expression,
whereas, the absence of FLOT1 in the proliferative stage
epithelium allowed detection of FLOT1 stimulated fol-
lowing IL11 treatment. Further, we suggest we were
unable to detect FLOT1 in primary hEEC by Western
blot because of the unfeasibly large number of cells
required to detect a low abundance protein (as demon-
strated by cytospin immunolocalisation) such as this.
FLOT1 is a lipid raft associated membrane protein
and is endocytosed from the plasma membrane into
intracellular compartments [28]. FLOT1 has also been
shown to reside in the plasma membrane, as well as in
the cytoplasm [29] as observed in our cytospin data.
Recent findings demonstrate that FLOT1 is associated
with cell motility and transformation, membrane traf-
ficking, phagocytosis and epidermal growth factor recep-
tor signaling [30]. Given that FLOT1 localises to the cell
membrane lipid rafts, it is not surprising that it is also
involved in cellular communication, such as cell-cell
contacts, focal adhesions, the T-cell cap, and synapses
[31]. Previous studies in several cell lines indicate that
FLOT1 localises to plasma membranes [32-35]. In our
study, FLOT1 immunostaining was primarily punctate
within the plasma membranes of hEEC and ECC-1 cells
and also in the glandular and luminal epithelial cells in
human endometrium. This is in agreement with a pre-
vious study that identified FLOT1 in punctate structures
or microdomains in plasma membranes of COS-7 cells,
Immunostaining- Flotillin-1 (FLOT1)
A B C
Primary hEEC cells
DE F
EEC-1 cells
Figure 7 Photomicrograph representing immunocytochemical staining for flotillin-1 (FLOT1) in human endometrial epithelial cells
(hEEC). Primary hEEC and the cell lines ECC-1 were treated with diluent or IL11 (100 ng/ml) for 24 h. Cytospins were prepared and subjected to
immunocytochemistry as described in the Materials & Methods. Positive staining for FLOT1 showed as brown pigment with blue nuclear
counterstain. (A, D) Negative IgG (B) Control primary EEC (C) IL11 100 ng/ml primary hEEC (E) Control ECC-1 (F) IL11 100 ng/ml ECC-1. Bars
represent 200 μm.
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membrane compartments [36]. The FLOT1 punctate
staining was primarily present apically in glandular and
luminal epithelial cells from mid-secretory or receptive
phase endometrium. In late-secretory phase endome-
trium, FLOT1 staining was present basolaterally in the
glands and did not appear punctate. This may have
been due to the overall lower level of staining seen in
late secretory phase compared to mid-secretory phase
endometrium, although it did not reach statistical signif-
icance. Studies carried out by our group in the past
have showed that IL11 localises in the glandular epithe-
lium and that it may be secreted apically into uterine
lumen and basally into the endometrium [10]. It is
tempting to speculate that the presence of FLOT1 in
combination with IL11 facilitates cell adhesion and
embryo implantation. Minimal FLOT1 protein was also
present in vascular endothelial and smooth muscle cells
- the functional significance for this remains to be
determined.
Conclusions
There is a wealth of evidence to support a role for IL11 in
endometrial receptivity [37,38]. IL11 regulates endometrial
epithelial cell adhesive properties [15] however the
mechanisms by which this occurs are poorly defined. This
study has identified membrane-associated proteins
ANXA2 and FLOT1 as IL11 downstream targets and sug-
gests that IL11 may regulate endometrial epithelial cell
adhesion at least in part via these proteins. Currently there
are no biochemical markers of endometrial receptivity.
This study suggests that FLOT1 may be useful as a marker
of receptivity as it is specifically upregulated in the recep-
tive phase. ANXA2 levels in the endometrium have
already been associated with receptivity [20]. It however
remains to be elucidated whether FLOT1 and ANXA2 are
altered in endometrium during the receptive phase of
women with subfertility and therefore indicate their utility
as markers of receptivity. Further studies on the roles of
FLOT1 and ANXA2 in endometrial epithelial cell adhe-
sion are also required to identify whether both factors may
be useful as treatment options for endometrial associated
subfertility.
This is the first study to demonstrate that proteomics
is a powerful approach in identifying plasma membrane
proteins that have may have a role in cell adhesion and
embryo-endometrial interactions. Our data further
defines mechanisms critical for endometrial receptivity
and embryo implantation and strengthens the evidence
that IL11 is an important regulator of endometrial
receptivity. Inadequate adhesion of the blastocyst to the
endometrial epithelium results in infertility [38]. Target-
ing IL11 and its regulated plasma membrane proteins
may help define new therapies to enhance or block
implantation.
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